Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases

Li, Yanwei and Li, Lin and Holscher, Christian (2016) Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. Reviews in the Neurosciences, 27 (7). pp. 689-711. ISSN 0334-1763

[thumbnail of review_manuscript]
PDF (review_manuscript)
review_manuscript.pdf - Accepted Version
Available under License Creative Commons Attribution-NonCommercial.

Download (949kB)


Incretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Due to their promising action on insulinotropic secretion and improving insulin resistance (IR), incretin-based therapies have become a new class of antidiabetic agents for the treatment of type 2 diabetes mellitus (T2DM). Recently, the links between neurodegenerative diseases and T2DM have been identified in a number of studies, which suggested that shared mechanisms, such as insulin dysregulation or IR, may underlie these conditions. Therefore, the effects of incretins in neurodegenerative diseases have been extensively investigated. Protease-resistant long-lasting GLP-1 mimetics such as lixisenatide, liraglutide, and exenatide not only have demonstrated promising effects for treating neurodegenerative diseases in preclinical studies but also have shown first positive results in Alzheimer’s disease (AD) and Parkinson’s disease (PD) patients in clinical trials. Furthermore, the effects of other related incretin-based therapies such as GIP agonists, dipeptidyl peptidase-IV (DPP-IV) inhibitors, oxyntomodulin (OXM), dual GLP-1/GIP, and triple GLP-1/GIP/glucagon receptor agonists on neurodegenerative diseases have been tested in preclinical studies. Incretin-based therapies are a promising approach for treating neurodegenerative diseases.

Item Type:
Journal Article
Journal or Publication Title:
Reviews in the Neurosciences
Uncontrolled Keywords:
?? alzheimer’s diseasedpp-iv inhibitorsglucagon-like peptide-1glucose-dependent insulinotropic polypeptideincretininsulin resistanceparkinson’s diseasetype 2 diabetes mellitusneuroscience(all) ??
ID Code:
Deposited By:
Deposited On:
30 Nov 2016 09:10
Last Modified:
07 Mar 2024 00:39